Updates

Ergomed

January 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Ergomed has acquired MedSource, a US-based specialist oncology and rare disease CRO, which doubles its US footprint in terms of employee numbers (+110 US employees to over 200 now). It adds 20 new clients and a >US$41m order book of future contracted revenues. Ergomed is paying US$18m upfront (c.10x 2021E EBITDA), with an earn-out of up to US$7m based on 2021 results, both structured 90% in cash, 10% in shares. In 2019, MedSource recorded service fee revenue of US$19.3m and adjusted EBITDA was US$1.3m, which makes the deal eps enhancing from day one. Numis has lifted its eps forecast by 5% for both FY20 and FY21 to 28p and 30.6p, respectively. A main buy at 295p in October ‘19, gain 258%. Strong hold for more. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

XLMedia

CML

Ergomed - Permira bids 1350p (September 2023)

Ergomed - 80%+ of this year’s forecast covered (September 2022)

Ergomed - Well set for an eps ‘beat’ (August 2022)

Ergomed (April 2022)

Ergomed - Buys specialist consultancy for £25.6m (March 2022)

Ergomed (October 2021)

Ergomed (May 2021)

Ergomed - "Hidden order bank" (October 2020)

Ergomed - Another big "beat" (August 2020)

Ergomed - Forecasts lifted again - by 5% (July 2020)

Ergomed - COVID-19 trial work underway (April 2020)

Ergomed - Earnings accretive deal (February 2020)

Ergomed - Taking a share in a winning streak (October 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X